“
TL;DR
Secondary outcomes include changes in ROADS scores, FVC percentages, ALSAQ-40 scores, and SSCMS scores at Weeks 12, 24, 36, and 48, as well as the rate and time to endpoint events (death, tracheostomy, or permanent-assisted ventilation).
Frontiers in Aging Neuroscience · 10 authors, 9 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
Secondary outcomes include changes in ROADS scores, FVC percentages, ALSAQ-40 scores, and SSCMS scores at Weeks 12, 24, 36, and 48, as well as the rate and time to endpoint events (death, tracheostomy, or permanent-assisted ventilation).
Secondary outcomes include changes in ROADS scores, FVC percentages, ALSAQ-40 scores, and SSCMS scores at Weeks 12, 24, 36, and 48, as well as the rate and time to endpoint events (death, tracheostomy, or permanent-assisted ventilation). The trial is registered at ChiCTR2100044085. This represents the first attempt to evaluate a TCM formulation for ALS using a standard evidence-based RCT methodology.